https://www.taxtmi.com/article/detailed?id=13991 Dependence on imported Active Pharmaceutical Ingredients (APIs) from China creates supply chain and quality vulnerabilities for India's pharmaceutical sector, while stringent international and domestic regulatory requirements, pricing pressures, competition, and patent disputes constrain export potential. Recommended responses include diversifying API sources, developing indigenous API manufacturing via incentives and public private partnerships, strengthening regulatory and quality standards to meet international norms, investing in R&D and biopharmaceutical innovation, and pursuing balanced IP policies alongside enhanced export market access and global public health collaboration. en-us Wed, 02 Apr 2025 08:58:57 +0530 Wed, 02 Apr 2025 08:58:57 +0530 TaxTMI RSS Generator https://www.taxtmi.com/article/detailed?id=13991 Dependence on imported Active Pharmaceutical Ingredients (APIs) from China creates supply chain and quality vulnerabilities for India's pharmaceutical sector, while stringent international and domestic regulatory requirements, pricing pressures, competition, and patent disputes constrain export potential. Recommended responses include diversifying API sources, developing indigenous API manufacturing via incentives and public private partnerships, strengthening regulatory and quality standards to meet international norms, investing in R&D and biopharmaceutical innovation, and pursuing balanced IP policies alongside enhanced export market access and global public health collaboration. Articles Customs - Import - Export - SEZ Wed, 02 Apr 2025 08:58:57 +0530 https://www.taxtmi.com/article/detailed?id=13991